BAM15
BAM15 scored 5.0 / 10 (⚖️ Neutral) on the BioHarmony scale as a Research chemical (mitochondrial protonophore uncoupler).
BAM15 is an experimental mitochondrial uncoupler that reversed diet-induced obesity and insulin resistance in mice without raising body temperature, the effect that made 2,4-dinitrophenol lethal. It has never been tested in a single human, and is sold only as an unregulated research chemical.
What is BAM15?
BAM15 is an experimental compound that makes cells burn more fuel by letting protons leak across the inner mitochondrial membrane. In mice it reversed obesity and insulin resistance without the overheating that killed people who took its predecessor.
It belongs to a class called mitochondrial uncouplers, the same broad mechanism as 2,4-dinitrophenol, the 1930s diet drug that caused fatal hyperthermia and was banned.
The reason BAM15 exists is that its designers found a way to keep the fuel-burning effect while removing the lethal one.
BAM15 uncouples mitochondria without depolarizing the plasma membrane of the whole cell, and at effective doses in animals it did not raise core body temperature (Kenwood et al. 2014). That single distinction is the reason anyone is interested in it.
The animal data is strong for a compound this early. Independent laboratories have shown BAM15 reversing established diet-induced obesity, sparing lean mass, improving insulin sensitivity, protecting kidneys from injury, and attenuating age-related muscle loss (Dantas et al. 2022).
What does not exist, at all, is a single human. There is no human pharmacokinetic study, no dose-finding trial, no safety data, and no company known to be advancing BAM15 into people. It is sold only as an unregulated research chemical.
The score of 5.0 is not a knock on the science. It is a statement that a compound nobody has ever dosed in a person cannot be recommended to one, however good the mouse data looks.
Terminology
A handful of terms decide how to read every claim about BAM15, and most of the confusion around the compound comes from blurring them. The single most important distinction is between the mitochondrial membrane and the plasma membrane, because BAM15's whole safety argument rests on acting on the first and sparing the second.
It also matters whether a finding is a metabolic-rate measurement in a cage or a felt human effect, since none of the second kind exist. The compound is constantly compared with an older drug, so the DNP vocabulary is worth having straight before weighing any safety claim.
- Mitochondrial uncoupler: A compound that lets protons cross the inner mitochondrial membrane without going through ATP synthase, so energy is released as heat and more fuel is burned to maintain ATP.
- Protonophore: The chemical term for a molecule that shuttles protons across a membrane. BAM15 is a protonophore selective for the mitochondrial membrane.
- Plasma membrane: The outer membrane of the whole cell. Depolarizing it is broadly toxic, and it is what BAM15 leaves alone but DNP does not.
- DNP: 2,4-dinitrophenol, an older uncoupler used for weight loss in the 1930s that caused fatal overheating and cataracts and remains sold illegally.
- DIO: Diet-induced obesity, the standard mouse model in which BAM15's fat-loss effect was shown.
- Ischemia-reperfusion injury: Tissue damage that occurs when blood flow returns after being cut off, the setting in which BAM15 protected mouse kidneys.
- Mitophagy: The cell's process of clearing damaged mitochondria, which BAM15 enhanced in aged muscle.
- NASH: Nonalcoholic steatohepatitis, an advanced fatty-liver disease that a BAM15-class compound was designed to treat.
BAM15 uncouples mitochondria without depolarizing the plasma membrane, and dose-dependently protects mice from acute renal ischemia-reperfusion injury. Kenwood and colleagues, Molecular Metabolism
How do you take BAM15?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Powder, dissolved or in capsule (gray-market research chemical) | None established in humans Animal metabolic studies dosed BAM15 in the diet, with mice self-consuming near 85 mg/kg per day | Forum reports of roughly 50 to 400 mg per day, cycled, units and basis unverified Self-experimentation is confined to bodybuilding and biohacking forums, not Reddit, and treats BAM15 as a milder DNP |
| Injection (intraperitoneal) | Solution, animal research use | None established in humans 3 mg/kg improved glucose tolerance and reduced fat pad mass in diet-induced obese mice | None Not a human route |
Protocols
Animal metabolic protocol (reference only) Clinical
- Dose
- Roughly 85 mg/kg per day in diet, or 3 mg/kg by injection
- Frequency
- Daily, chronic
- Duration
- Several weeks
This is the mouse paradigm that produced fat loss and insulin sensitization. It is not a human dose and cannot be scaled by body weight.
How this score is calculated →
What are the benefits of BAM15?
Upside contribution: 1.59
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.0 | 0.750 | |
| Breadth | 15% | 3.2 | 0.480 | |
| Evidence | 25% | 2.3 | 0.575 | |
| Speed | 10% | 2.6 | 0.260 | |
| Durability | 10% | 1.8 | 0.180 | |
| Bioindividuality | 15% | 2.3 | 0.345 | |
| Total | 2.590 | |||
| Baseline offset (constant) | −1.000 | |||
| Effective upside contribution | 1.590 |
Upside Rationale
The upside for BAM15 comes from one thing done unusually well for such an early compound. It has a coherent, independently replicated set of metabolic and organ-protective effects in animals, tied to a mechanism engineered to be safer than the uncouplers that came before it.
Fat loss without lean-mass loss, insulin sensitization at the level of clamp studies, kidney protection in two separate models, and muscle preservation in aging all point the same way, from more than one laboratory.
What the upside cannot include is any human confirmation, long-term data, or real-world track record, because none exists. The dimensions below credit the strength of the animal effect while holding evidence and durability near the floor.
Efficacy (3.0/5.0): BAM15's demonstrated effect in animals is large and clean. It reversed established diet-induced obesity and reduced fat mass in mice without reducing food intake or lean mass (Alexopoulos et al. 2020).
In a diabetic-mouse head-to-head it was competitive with semaglutide on metabolic physiology (Chen et al. 2024).
Efficacy is scored on the magnitude of the observed effect, and in the species where BAM15 has been tested that effect is strong. It stops at 3.0 because efficacy tracks real-world clinical magnitude, and there is no human result to tie it to. A dramatic mouse effect is a promising signal rather than a demonstrated human benefit, and the two are scored differently by design.
Breadth of Benefits (3.2/5.0): BAM15 acts through a broadly systemic mechanism, since every cell runs on mitochondria, and it carries a separate demonstrated animal endpoint in several distinct domains rather than one readout reinterpreted many ways.
There is metabolic benefit in obese mice, kidney protection in two injury models (Tsuji et al. 2023), liver-fat reduction from a NASH-focused program (Childress et al. 2020), and muscle preservation in aging (Dantas et al. 2022).
That is real multi-domain reach, but each domain carries a mouse endpoint, not a human one.
Evidence Quality (2.3/5.0): BAM15's evidence is consistent and multi-laboratory, which lifts it above a mechanism-only compound, but it is entirely preclinical, which caps it hard. The anti-obesity effect was shown by one group and replicated by another (Axelrod et al. 2020), and the kidney work appears in a high-impact journal.
Against that, there is not one human trial, no pharmacokinetic data in people, and no long-term or reproductive toxicology. The evidence dimension asks how confident a real person can be that BAM15 will work for them, and the honest answer with zero human data is low, however good the animal package. That gap is scored once here and in the low confidence label.
Speed of Onset (2.6/5.0): In mice, the metabolic benefits accrued over weeks of chronic dosing rather than after a single dose, which is the paradigm every metabolic BAM15 study used (Alexopoulos et al. 2020).
Because an uncoupler raises metabolic rate mechanically, some effect on energy expenditure would plausibly appear quickly, but nobody has measured a human onset because no human has been dosed.
The score reflects a mechanism that should act within days on metabolic rate but takes weeks to show a body-composition change, discounted because the first thing to move is a laboratory measurement rather than something a person feels.
Durability (1.8/5.0): BAM15's benefit is a continuous signal rather than a permanent change. The mechanism raises energy expenditure only while the compound is present, and its short mouse half-life means the effect depends on ongoing dosing.
No washout or durability-after-stopping data exists for BAM15 in any species, so the expectation that fat returns when dosing stops is inference from the mechanism rather than a measured finding. That places durability near the floor, where most interventions whose benefit tracks continued use sit.
Bioindividuality Upside (2.3/5.0): Because every cell relies on mitochondria, the mechanism should in principle apply broadly rather than to a narrow subgroup, which is a point in BAM15's favor.
But bioindividuality asks about the odds a specific person responds, and with no human data there is no responder profile, no predictor and no variance estimate to work from. The score reflects a mechanism that is plausibly universal offset by the absence of any human evidence about who actually responds.
What are the risks & downsides of BAM15?
Downside contribution: 1.61 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 3.4 | 1.020 | |
| Side effects | 15% | 2.2 | 0.330 | |
| Cost | 5% | 2.8 | 0.140 | |
| Effort | 5% | 1.8 | 0.090 | |
| Opportunity | 5% | 2.5 | 0.125 | |
| Dependency | 15% | 1.2 | 0.180 | |
| Reversibility | 25% | 1.3 | 0.325 | |
| Total | 2.210 | |||
| Harm subtotal × 1.4 | 2.597 | |||
| Opportunity subtotal × 1.0 | 0.355 | |||
| Combined downside | 2.952 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.612 |
Downside Rationale
The dominant downside for BAM15 is not a demonstrated toxicity. It is the combination of a mechanism intrinsically unforgiving about dose and a total absence of human data to establish where the safe dose sits.
Mitochondrial uncouplers work by raising metabolic rate, and pushed too far the same mechanism collapses energy production and generates dangerous heat, which is the history of the drug class. BAM15 was engineered to widen that margin and, in animals, it did.
But no human has been dosed, so the human window is unknown, and it is sold through unregulated channels where dose accuracy cannot be assumed. The dimensions below keep safety elevated while keeping demonstrated side-effect, dependency and reversibility concerns low.
Safety Risk (3.4/5.0): BAM15 has no demonstrated intrinsic catastrophic effect of its own, which keeps it below the 4.0 floor reserved for compounds with a proven life-threatening signal. In mice it produced no body-temperature rise and no toxicity markers at effective doses (Alexopoulos et al. 2020).
What keeps safety elevated is the mechanism class itself. An uncoupler's therapeutic window is inherently narrow, because the same action that raises metabolic rate can, at a higher dose, collapse ATP production and generate uncontrolled heat, and that human window has never been measured.
BAM15 improves on the DNP mechanism that caused fatalities, but a rodent-proven improvement is not a human safety guarantee, and no dosing experience exists in people.
Side Effect Profile (2.2/5.0): At the doses studied in animals, BAM15 was well tolerated, with no temperature elevation and no biochemical toxicity flagged in the metabolic studies. There is no human side-effect data to report, so this dimension reflects the mild, mechanism-expected profile seen in mice rather than a measured human complaint rate.
The realistic human concerns, if BAM15 were ever dosed correctly, would be the mild thermogenic effects of raised metabolic rate rather than a specific organ toxicity, which places side effects toward the low end while acknowledging that the human profile is unmeasured.
Financial Cost (2.8/5.0): There is no legitimate channel to price, because BAM15 is neither an approved drug nor a supplement. The only route is a research-chemical vendor selling powder for laboratory use, which lands in the mid-range on cost but carries the no-legitimate-channel problem that pushes the score up rather than down.
A buyer is paying an ordinary research-chemical price for a product with no manufacturing oversight and no guarantee it contains what the label claims, which is a poor value proposition regardless of the dollar figure.
Time and Effort Burden (1.8/5.0): Oral dosing is simple in principle, a small daily commitment rather than an appointment or a procedure. The short mouse half-life implies frequent dosing would be needed to sustain any effect, which adds a little burden.
Anyone using the gray-market powder also has to weigh and prepare doses without an approved product. On balance this is a low-burden intervention to administer, with the caveat that self-preparation adds an error surface a labeled product would not.
Opportunity Cost (2.5/5.0): For fat loss, BAM15 competes in a crowded field where better-evidenced options already exist, from resistance training and diet to approved drugs like semaglutide and tirzepatide.
Choosing an untested research chemical over any of those means accepting unknown risk for an unproven human benefit, which is a real opportunity cost even though BAM15 does not physically interfere with other interventions. The score reflects the presence of concrete, better-established alternatives for the same goal.
Dependency and Withdrawal (1.2/5.0): BAM15 has no addictive mechanism, no craving, no tolerance and no withdrawal syndrome. It is a metabolic-rate manipulation, so stopping it simply returns metabolic rate toward baseline. The loss of benefit on stopping is a durability matter, scored above, rather than a dependency one. This places dependency at the floor.
Reversibility (1.3/5.0): BAM15 appears to clear cleanly. Its short half-life in animals means the compound itself washes out quickly, with no evidence of a permanent structural change and no taper described.
The mechanism is a live signal that stops when the compound is gone, so stopping is clean in the sense that matters for this dimension. The score sits near the floor, with the honest caveat that clean washout is inferred from animal pharmacokinetics rather than measured in people.
Is BAM15 worth it?
BAM15 is one of the most promising preclinical compounds in the metabolic field and one of the worst things a person could buy right now, and both statements come from the same fact. The science is excellent and none of it is in humans.
The mechanism is real and cleverly engineered, the animal data is replicated across independent laboratories and multiple organ systems, and the safety improvement over DNP is a published distinction rather than a marketing line.
But there is no human pharmacokinetic study, no dose-finding, no safety data, no approved supply, and a newer uncoupler that reviewers consider closer to the clinic. Score it as a compound to watch through its first human trial, not one to source from a research-chemical vendor and dose by guesswork. The 5.0 will move the moment a Phase 1 exists.
✅ Best for: Researchers, metabolic-disease scientists and clinicians who need a reference point for where mitochondrial uncouplers currently sit as a therapeutic strategy. People tracking the obesity and NASH pipelines who want to understand the mechanism that keeps drawing investment despite DNP's history.
Anyone comparing next-generation uncouplers who needs the strongest-published example of the class as a benchmark. Writers and analysts covering the metabolic-rate space who want the honest state of the evidence rather than the vendor version.
❌ Avoid if: You are looking for a fat-loss compound to take, since no human has ever been dosed and no safe human dose exists. You would be buying research-chemical powder, which carries no purity guarantee, no dose verification and no recourse. You have any cardiac condition, since the uncoupler class carries a theoretical cardiac-strain concern never characterized in people.
You are inclined to weight-scale a mouse dose to your own body, which is the guesswork that made older uncouplers deadly. You want an evidence-backed metabolic intervention today, in which case an approved option like metformin or a GLP-1 drug has human data BAM15 lacks.
What is BAM15 best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ○ Body Composition / Fat Loss Primary | 4.5 | The strongest use case, and still animal-only. BAM15 reversed established diet-induced obesity and cut fat mass in mice without touching lean mass or food intake, replicated across independent labs (Alexopoulos et al. 2020; Axelrod et al. 2020), and held up against semaglutide in a head-to-head diabetic-mouse study (Chen et al. 2024). The score is capped below 5.0 because no human has ever been measured, so the fat-versus-lean split and the dose that achieves it in people are unknown. |
| ○ Metabolic Health Primary | 4.5 | BAM15 improved insulin sensitivity across tissues in hyperinsulinemic-euglycemic clamp studies in diet-induced obese mice, the most rigorous mechanistic metabolic readout available in animals (Alexopoulos et al. 2020), with an independent lab confirming improved glycemic control (Axelrod et al. 2020). It stays below 5.0 for the same reason every use case here does, which is that no human metabolic data of any kind exists. |
| ○ Blood Sugar / Glycemic Control Primary | 4.0 | Improved glucose tolerance and glycemic control are consistent animal findings (Axelrod et al. 2020), but no human glucose data exists. |
| ○ Kidney Function Primary | 4.5 | The best-replicated non-metabolic signal. BAM15 dose-dependently protected mice from acute renal ischemia-reperfusion injury in its founding paper (Kenwood et al. 2014) and treated sepsis-associated kidney injury in a high-impact follow-up (Tsuji et al. 2023). Capped below 5.0 because it is entirely preclinical. |
| ○ Longevity / Lifespan Primary | 3.0 | Mild mitochondrial uncoupling is a long-standing longevity hypothesis, and BAM15 improved several aging-relevant endpoints in mice, but no lifespan study exists for it in any species. |
| ○ Mitochondrial | 4.0 | Direct mechanism, since BAM15 is a mitochondrial protonophore and mitochondrial function is what it acts on (Kenwood et al. 2014). Preclinical only. |
| ○ Liver / Detoxification | 3.5 | A dedicated medicinal-chemistry program built BAM15-class uncouplers for nonalcoholic steatohepatitis and reduced liver fat and inflammation in mouse models (Childress et al. 2020). No human liver data. |
| ○ Antioxidant / Oxidative Stress | 3.5 | Mild uncoupling lowers mitochondrial reactive oxygen species, and a strong antioxidant effect accompanied the metabolic benefit in mice (Alexopoulos et al. 2020). Animal only. |
| ○ Healthspan | 3.5 | Sarcopenia, kidney and metabolic findings are healthspan-adjacent, but all are single-organ animal endpoints rather than a demonstrated healthspan outcome (Dantas et al. 2022). |
| ○ Autophagy | 3.0 | BAM15 enhanced skeletal-muscle mitophagy and mitochondrial quality control in aged mice (Dantas et al. 2022). Mechanistic, preclinical. |
| ○ Anti-Inflammatory | 3.0 | BAM15 lowered inflammatory lipid species in obese mice and reduced renal neutrophil infiltration in sepsis (Tsuji et al. 2023). Animal only. |
| ○ Geriatric / Aging Population | 3.0 | The sarcopenia work was done in aged mice, so the aging-population relevance is real but remains preclinical (Dantas et al. 2022). |
Frequently Asked Questions
Is BAM15 safe for humans to take?
Nobody knows, because not one human has ever been dosed with BAM15 in a registered trial. Its safety case rests entirely on mice, where it did not raise body temperature and showed no toxicity markers at the effective dose (Alexopoulos et al. 2020). That is reassuring next to 2,4-dinitrophenol, which it was designed to improve on, but a rodent margin is not a human margin, and the therapeutic window in people is completely unmeasured.
How is BAM15 different from DNP?
BAM15 uncouples only the mitochondrial membrane, while DNP also collapses the plasma-membrane potential across the whole cell, which is what drives its runaway heat production and cell death (Kenwood et al. 2014). In animals BAM15 did not raise core body temperature at effective doses. That is a real, published mechanistic distinction rather than marketing, but it is proven in rodents, not in people.
Does BAM15 actually cause fat loss?
In mice, clearly. BAM15 reversed established diet-induced obesity and cut fat mass without reducing food intake or lean mass, and it held up against semaglutide in a diabetic-mouse comparison (Chen et al. 2024). In humans, there is no evidence at all, because the compound has never been tested in a person. Any fat-loss claim you see for BAM15 is an extrapolation from rodent studies, not a demonstrated human result.
Can you buy BAM15 legally?
Not as a legitimate medicine. BAM15 is not approved as a drug or a dietary supplement anywhere, so it is sold only as a research chemical labeled not for human consumption, through unregulated vendors with no purity testing. There is no pharmaceutical-grade product, no dose-verified capsule and no recourse if a vial contains the wrong thing. That sourcing risk sits on top of the fact that no human dose has ever been established.
What is the correct BAM15 dosage?
There is no established human dose, full stop. Animal studies used roughly 3 mg/kg by injection or near 85 mg/kg per day in food, and a mouse half-life around three hours means the compound clears quickly (Kenwood et al. 2014). Those numbers cannot be scaled to a person by body weight, and doing so is exactly the guesswork that made older uncouplers dangerous. Any milligram figure sold online is unsupported.
What does BAM15 do to the kidneys?
In mice, BAM15 protects the kidneys. Its founding study showed dose-dependent protection from acute ischemia-reperfusion injury (Kenwood et al. 2014), and a later high-impact paper showed it treats sepsis-associated kidney injury by lowering mitochondrial reactive oxygen species and improving survival (Tsuji et al. 2023). This is BAM15's best-replicated non-metabolic effect, but like everything else it has only been shown in animals.
How fast would BAM15 work?
Nobody knows the human timeline, because no person has been dosed. In mice, the metabolic benefits like fat loss and insulin sensitivity built up over weeks of chronic dosing rather than appearing after a single dose (Alexopoulos et al. 2020). Because an uncoupler raises metabolic rate mechanically, some effect on energy expenditure would likely be quicker, but that is inference rather than a measured human onset.
Is BAM15 the most advanced mitochondrial uncoupler?
It is the most-published, but not necessarily the front-runner. Review literature describes a newer uncoupler, SHC517, as the leading candidate for translational development, which suggests industry has not selected BAM15 itself as a clinical lead despite its deep animal record. No biotech licensing or human-trial program for BAM15 was found, and a short half-life plus formulation work on delivery vehicles points to real pharmacokinetic obstacles for the free compound.
What could change BAM15's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The single event that would move BAM15's score is a first-in-human trial, and it could move it in either direction by roughly a point. A clean Phase 1 establishing a tolerable human dose and confirming no hyperthermia would lift Evidence out of the low band and raise confidence toward Moderate.
A human safety signal, or a trial showing the rodent metabolic effect does not translate, would cut Efficacy and Evidence together and drop it into caution. The nearer-term possibility is that a company licenses BAM15 or a close analog and announces a development program, which would raise confidence without yet changing the human evidence.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A clean Phase 1 establishes a tolerable human dose with no hyperthermia | Evidence 2.3 to 3.3, Safety 3.4 to 3.0, confidence Low to Moderate | 5.9 / 10 👍 Worth trying |
| A Phase 2 confirms the metabolic effect translates to humans | Efficacy 3.0 to 4.0, Evidence 2.3 to 3.6, Breadth 3.2 to 3.6 | 6.6 / 10 👍 Worth trying |
| A biotech licenses BAM15 and opens a registered development program | Evidence 2.3 to 2.8, confidence rises | 5.3 / 10 ⚖️ Neutral |
| A first human trial surfaces a dose-limiting safety signal | Safety 3.4 to 4.0, Evidence 2.3 to 2.8 | 4.4 / 10 ⚠️ Caution |
| The rodent fat-loss effect fails to translate in an early human study | Efficacy 3.0 to 2.0, Evidence 2.3 to 2.8 | 4.5 / 10 ⚖️ Neutral |
| A newer uncoupler like SHC517 reaches humans first and BAM15 is shelved | Evidence stays 2.3, Opportunity 2.5 to 3.2 | 4.8 / 10 ⚖️ Neutral |
📊 How BioHarmony Scoring Works
BAM15 upside total 1.59, downside total 1.612, giving a net of -0.02 and a score of 5.0 out of 10.Every intervention is rated 1 to 5 on six upside dimensions and seven downside dimensions, then weighted. A score of 5.0 out of 10 means the upside and the downside cancel out, not that the intervention is average. Harm-type downsides carry a 1.4 multiplier because a health risk is not interchangeable with a cost or an inconvenience; cost, effort and opportunity cost count at face value.| Upside dimension | Weight | BAM15 | |---|---|---| | Efficacy | 25% | 3.0 | | Breadth of benefits | 15% | 3.2 | | Evidence quality | 25% | 2.3 | | Speed of onset | 10% | 2.6 | | Durability | 10% | 1.8 | | Bioindividuality | 15% | 2.3 || Downside dimension | Weight | BAM15 | |---|---|---| | Safety risk | 30% | 3.4 | | Side effect profile | 15% | 2.2 | | Financial cost | 5% | 2.8 | | Time and effort | 5% | 1.8 | | Opportunity cost | 5% | 2.5 | | Dependency | 15% | 1.2 | | Reversibility | 25% | 1.3 || Tier | Range | Meaning | |---|---|---| | ✅ Top-tier | 8.8 to 10.0 | Worth building a routine around | | 💪 Strong recommend | 7.0 to 8.7 | Clear net benefit for most people | | 👍 Worth trying | 5.8 to 6.9 | Favourable odds, worth a personal test | | ⚖️ Neutral | 4.5 to 5.7 | Upside and downside roughly cancel | | ⚠️ Caution | 3.0 to 4.4 | Downside usually wins | | 🚫 Skip | 0.0 to 2.9 | Not worth it |
This report is informational and is not medical advice. BAM15 is an unapproved research chemical that has never been tested in humans. Nothing here is a recommendation to obtain or use it. Talk to your own clinician before making any change to medication or treatment.
BioHarmony Engine v2.0
Key Evidence Sources
- Kenwood et al. 2014, Molecular Metabolism: identification of BAM15 as a mitochondrial uncoupler that does not depolarize the plasma membrane. The founding paper. Established that BAM15 uncouples mitochondria without collapsing the plasma-membrane potential, the mechanistic basis for its safety margin over DNP, and showed dose-dependent protection from acute renal ischemia-reperfusion injury in mice.
- Alexopoulos et al. 2020, Nature Communications: BAM15 reverses diet-induced obesity and insulin resistance in mice. The pivotal metabolic study. BAM15 reversed established obesity and decreased fat mass without changing food intake, lean mass or core body temperature, decreased hepatic fat, and improved insulin sensitivity across tissues in clamp studies. No toxicity markers at the effective dose.
- Axelrod et al. 2020, EMBO Molecular Medicine: BAM15-mediated uncoupling protects against obesity and improves glycemic control. Independent replication of the anti-obesity and glycemic effect by a different laboratory, which is what raises the animal evidence above a single-group finding.
- Childress et al. 2020, Journal of Medicinal Chemistry: oxadiazolopyrazine uncouplers for nonalcoholic steatohepatitis. A medicinal-chemistry program on BAM15-class compounds explicitly targeting NASH, reducing liver triglycerides and inflammation in mouse models without altering body temperature. Related BAM15-class analog, cited for the liver use case.
- Tsuji et al. 2023, Journal of Clinical Investigation: BAM15 treats mouse sepsis and sepsis-associated kidney injury. High-impact follow-up linking reduced mitochondrial reactive oxygen species and circulating mitochondrial DNA to improved survival and less tubule damage. The strongest non-metabolic BAM15 signal.
- Dantas et al. 2022, Journal of Cachexia Sarcopenia and Muscle: mitochondrial uncoupling attenuates sarcopenic obesity. BAM15 attenuated age-related muscle loss by enhancing skeletal-muscle mitophagy and mitochondrial quality control in aged mice, the basis for the healthspan and geriatric use cases.
- Zunica et al. 2021, Cancer and Metabolism: BAM15 suppresses breast cancer growth via mitochondrial targeting. An off-target oncology finding showing the mitochondrial-uncoupling mechanism suppresses breast-cancer cell proliferation, included for mechanistic breadth rather than as a cancer recommendation.
- Chen et al. 2024, Biochimica et Biophysica Acta Molecular Basis of Disease: head-to-head of BAM15 against semaglutide, rosiglitazone and calorie restriction. Directly compared BAM15 against pharmacologically validated anti-obesity agents in diabetic mice, positioning it as competitive on metabolic physiology in that model.
- Kenwood et al. 2015, Bioorganic and Medicinal Chemistry Letters: structure-activity relationships of furazano-pyrazine uncouplers. The structure-activity work that generated BAM15 analogs and characterized what makes a mitochondria-selective uncoupler, useful context for why the class is being optimized.
- Jin et al. 2026, Cancer Biology and Medicine: mitochondrial uncoupling inhibits serine catabolism in metastatic breast cancer. A recent mechanistic cancer-metabolism paper extending the uncoupling mechanism to serine catabolism, cited as evidence the mechanism remains an active research area.
What does the evidence say about BAM15?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Emerging
Citations: Kenwood 2014, Alexopoulos 2020, Axelrod 2020, Tsuji 2023, Dantas 2022
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- ALT During | Expected Watch
- AST During | Expected Watch
- Fasting Glucose During | Expected Down
- Resting Heart Rate During | Expected Watch
Pulse Dimensions to Watch
- Body During | Expected Down | Primary
- Energy During | Expected Watch | Primary
- Calm During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Overheating or unusual sweating Scale 1-5 | During | Expected Watch
- Resting heart rate on waking Scale 1-5 | During | Expected Watch
- Unintended rapid weight loss Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Fever, profuse sweating or a racing heart: stop immediately and seek care, since that is the DNP toxicity pattern.
- Confusion, muscle rigidity or dark urine: stop and seek emergency care, since that pattern points to a rhabdomyolysis or hyperthermia crisis.
- Any product without a verified certificate of analysis: do not take it, because no approved supply of BAM15 exists anywhere.
Other interventions for Body Composition
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.590 − 1.612 = -0.022
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.022 / 5.36) × 5 = 5.0 / 10
